As the UK market grapples with the repercussions of faltering trade data from China, the FTSE 100 and FTSE 250 indices have experienced declines, reflecting broader global economic concerns. In such a climate, identifying stocks trading below their estimated value can present unique opportunities for investors looking to navigate these challenging conditions by focusing on fundamental strengths and potential for long-term growth.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Name Current Price Fair Value (Est) Discount (Est) Moonpig Group (LSE:MOON) £2.275 £3.98 42.9% Marlowe (AIM:MRL) £4.43 £8.41 47.3% LSL Property Services (LSE:LSL) £3.25 £6.00 45.8% Hostelworld Group (LSE:HSW) £1.36 £2.55 46.7% Gooch & Housego (AIM:GHH) £6.10 £11.32 46.1% Franchise Brands (AIM:FRAN) £1.50 £2.66 43.6% Deliveroo (LSE:ROO) £1.769 £3.21 44.8% Burberry Group (LSE:BRBY) £12.10 £24.04 49.7% Benchmark Holdings (AIM:BMK) £0.244 £0.45 45.4% AstraZeneca (LSE:AZN) £104.02 £186.93 44.4%

Click here to see the full list of 55 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

NIOX Group

Overview: NIOX Group Plc designs, develops, and commercializes medical devices for asthma diagnosis, monitoring, and management globally with a market cap of £283.94 million.

Operations: The company generates revenue primarily from its NIOX® segment, which accounted for £41.80 million.

Estimated Discount To Fair Value: 37.3%

NIOX Group is trading at £0.68, significantly below its estimated fair value of £1.08, suggesting it may be undervalued based on cash flows. Despite a decline in profit margins from 25.8% to 8.1%, earnings are forecast to grow significantly at 37.5% annually, outpacing the UK market's growth rate of 14.3%. However, recent insider selling and the cancellation of a potential acquisition by Keensight Capital highlight some uncertainties surrounding the stock's future prospects.

Our comprehensive growth report raises the possibility that NIOX Group is poised for substantial financial growth. Get an in-depth perspective on NIOX Group's balance sheet by reading our health report here.AIM:NIOX Discounted Cash Flow as at Jul 2025

AstraZeneca

Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of approximately £161.30 billion.

Operations: AstraZeneca's revenue primarily comes from its biopharmaceuticals segment, which generated $54.98 billion.

Estimated Discount To Fair Value: 44.4%

AstraZeneca is trading at £104.02, significantly below its estimated fair value of £186.93, indicating potential undervaluation based on cash flows. Despite high debt and a history of unstable dividends, AstraZeneca's earnings are forecast to grow 15.33% annually, outpacing the UK market's growth rate of 14.3%. Recent US approval for Datroway in treating EGFR-mutated NSCLC could enhance revenue streams but large one-off items have previously impacted financial results.

Story Continues

The analysis detailed in our AstraZeneca growth report hints at robust future financial performance. Take a closer look at AstraZeneca's balance sheet health here in our report.LSE:AZN Discounted Cash Flow as at Jul 2025

Moonpig Group

Overview: Moonpig Group PLC operates as an online retailer offering greeting cards and gifts in the Netherlands and the United Kingdom, with a market capitalization of £751.08 million.

Operations: The company's revenue segments include £48.85 million from Greetz, £262 million from Moonpig, and £39.21 million from Experiences.

Estimated Discount To Fair Value: 42.9%

Moonpig Group is trading at £2.28, below the estimated fair value of £3.98, suggesting undervaluation based on cash flows. Despite a net loss of £11.08 million for the year ending April 2025 and high debt levels, Moonpig's revenue growth is expected to outpace the UK market at 7.9% annually. The company completed a share buyback worth £25 million and forecasts significant earnings growth, potentially becoming profitable within three years despite negative shareholders' equity concerns.

Upon reviewing our latest growth report, Moonpig Group's projected financial performance appears quite optimistic. Click here and access our complete balance sheet health report to understand the dynamics of Moonpig Group.LSE:MOON Discounted Cash Flow as at Jul 2025

Summing It All Up

Dive into all 55 of the Undervalued UK Stocks Based On Cash Flows we have identified here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Want To Explore Some Alternatives?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:NIOX LSE:AZN and LSE:MOON.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]